Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia

  title={Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia},
  author={Sandro Gentile and Salvatore Turco and Giuseppina Guarino and Carla Sasso and Massimo Amodio and P Magliano and Teresa Salvatore and Gerardo Corigliano and Mariano Agrusta and Giovanni de Simone and Iole Gaeta and Biagio Oliviero and Roberto Torella},
Although there is little information from primary or secondary prevention trials on cholesterol‐lowering medication in diabetic patients, the reduction of elevated cholesterol is widely recommended for this group. The American Diabetes Association (ADA) recommends drug therapy in diabetic patients if low density lipoprotein (LDL)‐cholesterol remains at > 130 mg/dl, or > 100 mg/dl in patients with macroangiopathy, after dietary intervention. When cholesterol‐lowering medication is indicated, the… 
Comparative efficacy and safety of atorvastatin, simvastatin and lovastatin in the management of dyslipidemic Type 2 diabetic patients
The results of this study confirm that among statins, atorvastatin is a better choice for the control of hyperlipidemia in Type 2 diabetic patients.
Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.
Atorvastatin was effective at reducing the risk of a first major cardiovascular event, including stroke, in a large, placebo-controlled, multicentre trial in patients with type 2 diabetes and at least one other coronary heart disease (CHD) risk factor, but without markedly elevated LDL-cholesterol levels.
Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics
The results of the study will provide important information on the efficacy and safety of atorvastatin to support its use in patients with an impaired renal function who are at a high risk of vascular morbidity and mortality.
Atorvastatin provides pronounced lipid lowering in a broad range of individuals with hypercholesterolaemia and, as such, is an appropriate first-line therapy for patients at low to high risk of coronary heart disease.
Switching From Atorvastatin to Simvastatin in Patients at High Cardiovascular Risk: Effects on Low-Density Lipoprotein Cholesterol
A large proportion of patients who switch from atorvastatin to simvastsatin are prescribed doses that are not therapeutically equivalent, and these patients were significantly less likely to meet LDL-C treatment goals compared with patients who remained on atorVastatin.
Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
  • F. Hobbs
  • Medicine, Biology
    International journal of cardiology
  • 2006
Combined Analysis of Pharmacokinetic and Efficacy Data of Preclinical Studies with Statins Markedly Improves Translation of Drug Efficacy to Human Trials
It is shown for the first time that hepatic uptake of statins is related to their cholesterol-lowering efficacy and evidence is provided that combined PK and efficacy studies can substantially improve the translational value of the E3L mouse model in the case of statin treatment is provided.
Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis
Abstract Objective To compare the efficacy of different statin treatments by intensity on levels of non-high density lipoprotein cholesterol (non-HDL-C) for the prevention of cardiovascular disease
Statins as a Primary Prevention: Which One is Most Effective? A Systematic Review and Meta-Analysis
Statins were shown to improve the lipid triad by lowering LDL-C and TGs and increasing HDL-C, in agreement with previous research, and clinicians should have knowledge of most appropriate statin treatments for patients based on individual lipid levels.


Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
Atorvastatin was well tolerated by hyperlipidemic patients, had an acceptable safety profile, and provided greater reduction in cholesterol than other previously reported HMG-CoA reductase inhibitors.
Gemfibrozil Alone and in Combination With Lovastatin for Treatment of Hypertriglyceridemia in NIDDM
The beneficial effects of the combination therapy on lipoprotein levels in markedly hypertriglyceridemic NIDDM patients could decrease the risk of development of both acute pancreatitis and CHD.
Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus.
The beneficial effects of lovastatin on plasma lipid levels in patients with NIDDM could decrease the risk of the development of coronary heart disease.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
It is demonstrated that the benefit of cholesterol-lowering therapy extends to the majority of patients with coronary disease who have average cholesterol levels and was also greater in patients with higher pretreatment levels of LDL cholesterol.